Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Brander who wrote (2885)	3/20/1998 8:16:00 PM
From: Hank	Read Replies (2) \| Respond to of 7041

Brad, As a Dr. you should know that side effects are an important part of the decision process when the FDA considers whether a drug offers added benefits to the currently available treatment. Yes, there is often no way to determine patient to patient variability in terms of efficacy. However, there is clearly a way to determine added benefit through the extent and type of adverse side effects. Zoloft, for example, has been shown to cause headaches in 20.3% of the patients who take it, male impotence in 15.5% of the male patients who take it, and somnolence in 13.4% of the patients who take it. Plaxil, by comparison, will cause somnolence in 12.7% to 21.6% of the patients depending on the dose, impotence in 1.5% of patients, and 0% incidence of headaches. Clearly, there are subsets of the patient population that can gain a maximum benefit from taking one or the other but not both and these differences are easily defined prior to FDA approval. The same is true over every other drug in very other class. Hank